Targeting a MET fusion gene with crizotinib in one pHGG patient resulted in a partial response with rapid tumor relapse [7], yet no lasting response after MET inhibition has been demonstrated for MET-driven pHGGs so far. The gene discussed is MET; the disease is neoplasm.